Related Experiment Video
Updated: Apr 8, 2026
10:00
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
13.9K
Interferon-γ polymorphism and hepatocellular carcinoma susceptibility: a meta analysis
Jing Sun1, Kai Liao1, Yuefei Wang1
1Department of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University Chongqing, China.
Summary
This meta-analysis found no significant link between the Interferon-gamma (IFN-γ) rs2430561 polymorphism and hepatocellular carcinoma (HCC) risk. Further research is needed to clarify the role of this genetic variation in cancer development.
Area of Science:
- Immunogenetics
- Oncology
- Molecular Epidemiology
Background:
- Interferon-gamma (IFN-γ) exhibits antiviral and antitumor properties.
- The IFN-γ rs2430561 polymorphism influences immune regulation.
- Previous studies on rs2430561 and hepatocellular carcinoma (HCC) susceptibility lack consistency.
Purpose of the Study:
- To conduct a meta-analysis evaluating the association between the IFN-γ rs2430561 polymorphism and HCC incidence.
- To synthesize existing epidemiologic and molecular data on this genetic variation and liver cancer risk.
Main Methods:
- A systematic literature search was performed across multiple databases.
- Six relevant human studies were included in the meta-analysis.
- Various genetic models (allele, homozygote, heterozygote, dominant, recessive) were analyzed, with sensitivity and publication bias tests performed.
Main Results:
- The T allele of rs2430561 showed a non-significant, moderate increase in HCC risk (OR=1.12).
- No significant association was found across different genetic models or in subgroup analyses for HBV-infected HCC.
- Sensitivity and publication bias tests confirmed the reliability of the combined results.
Conclusions:
- There is no robust statistical evidence linking the IFN-γ rs2430561 polymorphism to HCC susceptibility.
- The findings suggest this specific genetic variation may not be a significant risk factor for liver cancer.
More Related Videos
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
32
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
32
01:25Hepatitis
46
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
46
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
119
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
119
01:27Pharmacogenetics of Drug Metabolism: Overview
137
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
137
01:29Pharmacogenomics: Identification of New Drug Targets
88
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
88
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
347
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
347